Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Activision Blizzard, United Continental Holdings Set to Join the S&P 500 PR Newswire NEW YORK, Aug. 27, 2015 NEW YORK, Aug. 27, 2015 /PRNewswire/ -- S&P Dow Jones Indices will make the...
Hospira Announces First Installation of Plum 360™ Infusion System With Hospira MedNet™ -- Next-generation infusion system offers expanded drug library and EMR interoperability -- PR Newswire LAKE...
Hospira and Cerner Expand Agreement to Advance Integration of I.V.-EMR Technology PR Newswire LAKE FOREST, Ill., and KANSAS CITY, Mo., Aug. 25, 2015 LAKE FOREST, Ill., and KANSAS CITY, Mo., Aug...
TGA Approves First mAb Biosimilar Hospira's Inflectra™ registered in Australia PR Newswire MELBOURNE, Australia, Aug. 19, 2015 MELBOURNE, Australia, Aug. 19, 2015 /PRNewswire/ -- Hospira today...
Hospira Applauds UK's NICE for Issuing Adoption Resource to Help Drive the Introduction of Biosimilars PR Newswire LAKE FOREST, Illinois, Aug. 13, 2015 LAKE FOREST, Illinois, Aug. 13, 2015...
Technical Briefing on Drugs - Generic Equities -- Hospira, Mallinckrodt, Momenta Pharma, Catalyst Pharma, and Lannett PR Newswire NEW YORK, August 7, 2015 NEW YORK, August 7, 2015 /PRNewswire/...
Hospira Reports Second-Quarter 2015 Results PR Newswire LAKE FOREST, Ill., July 29, 2015 LAKE FOREST, Ill., July 29, 2015 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider...
Hospira Announces U.S. Launch of Generic Bivalirudin for Injection PR Newswire LAKE FOREST, Ill., July 16, 2015 LAKE FOREST, Ill., July 16, 2015 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the...
Hospira to Announce Second-Quarter 2015 Results on July 29, 2015 PR Newswire LAKE FOREST, Ill., July 15, 2015 LAKE FOREST, Ill., July 15, 2015 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the...
New results from first real-world study show comparable effectiveness and safety of Hospira's Inflectra™ (infliximab) in patients with rheumatic diseases switched from reference infliximab...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
